BR112017025367A2 - derivados tricíclicos contendo nitrogênio tendo atividade inibidora de replicação de hiv - Google Patents

derivados tricíclicos contendo nitrogênio tendo atividade inibidora de replicação de hiv

Info

Publication number
BR112017025367A2
BR112017025367A2 BR112017025367-4A BR112017025367A BR112017025367A2 BR 112017025367 A2 BR112017025367 A2 BR 112017025367A2 BR 112017025367 A BR112017025367 A BR 112017025367A BR 112017025367 A2 BR112017025367 A2 BR 112017025367A2
Authority
BR
Brazil
Prior art keywords
substituted
unsubstituted
group
hydrogen atom
alkyl group
Prior art date
Application number
BR112017025367-4A
Other languages
English (en)
Japanese (ja)
Inventor
Tamura Yoshinori
Kawasuji Takashi
Sugiyama Shuichi
Matsumura Akira
Akiyama Toshiyuki
Tomida Yutaka
Original Assignee
Shionogi & Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co., Ltd. filed Critical Shionogi & Co., Ltd.
Publication of BR112017025367A2 publication Critical patent/BR112017025367A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/06—Peri-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

é fornecido: um novo composto tendo ação antiviral, especialmente atividade inibidora de replicação do hiv; e um produto farmacêutico, especialmente um agente anti-hiv que contém este composto. um composto representado por fórmula (i). (na fórmula, a3 é cr3a, cr3ar3b, n ou nr3c; cada dentre r3a, r3b, r4a e r4b independentemente representa um átomo de hidrogênio, um átomo de halogênio, um grupo ciano, um grupo alquila substituída ou não substituída, um grupo alquinila substituída ou não substituída ou um grupo carbocíclico não aromático substituído ou não substituído; r3c representa um átomo de hidrogênio, um grupo alquila substituída ou não substituída ou um grupo carbocíclico não aromático substituído ou não substituído; anel t1 representa um anel heterocíclico não aromático contendo nitrogênio substituído ou não substituído; r1 representa um átomo de hidrogênio, um átomo de halogênio, um grupo ciano ou um grupo alquila substituído ou não substituído; cada r2 independentemente representa um grupo alquila substituída ou não substituída ou similares; n é 1 ou 2; r3 representa um grupo carbocíclico aromático substituído ou não substituído ou similares; r4 representa um átomo de hidrogênio ou um grupo protetor carbóxi).
BR112017025367-4A 2015-05-29 2016-05-27 derivados tricíclicos contendo nitrogênio tendo atividade inibidora de replicação de hiv BR112017025367A2 (pt)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
JP2015109547 2015-05-29
JP2015-109547 2015-05-29
JP2015-170222 2015-08-31
JP2015170222 2015-08-31
JP2015223036 2015-11-13
JP2015-223036 2015-11-13
JP2016054215 2016-03-17
JP2016-054215 2016-03-17
PCT/JP2016/065702 WO2016194806A1 (ja) 2015-05-29 2016-05-27 Ｈｉｖ複製阻害作用を有する含窒素３環性誘導体

Publications (1)

Publication Number Publication Date
BR112017025367A2 true BR112017025367A2 (pt) 2018-08-07

Family

ID=57442245

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017025367-4A BR112017025367A2 (pt) 2015-05-29 2016-05-27 derivados tricíclicos contendo nitrogênio tendo atividade inibidora de replicação de hiv

Country Status (16)

Country Link
US (2) US10494380B2 (pt)
EP (1) EP3305789A4 (pt)
JP (2) JP6614585B2 (pt)
KR (1) KR20180011267A (pt)
CN (2) CN111138458A (pt)
AU (1) AU2016271762B2 (pt)
BR (1) BR112017025367A2 (pt)
CA (1) CA2987384A1 (pt)
HK (1) HK1253539A1 (pt)
IL (1) IL255580B (pt)
MA (1) MA43120A (pt)
MX (1) MX2017015256A (pt)
RU (1) RU2720145C2 (pt)
SG (1) SG11201709634QA (pt)
TW (1) TWI700284B (pt)
WO (1) WO2016194806A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2970282B1 (en) 2013-03-15 2019-08-21 Incyte Holdings Corporation Tricyclic heterocycles as bet protein inhibitors
EP3019502B1 (en) 2013-07-08 2017-05-17 Incyte Holdings Corporation Tricyclic heterocycles as bet protein inhibitors
US9399640B2 (en) 2013-11-26 2016-07-26 Incyte Corporation Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
US9309246B2 (en) 2013-12-19 2016-04-12 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
MY180775A (en) 2014-04-23 2020-12-09 Incyte Corp 1h-pyrrolo[2,3-c]pyridin-7(6h)-ones and pyrazolo[3,4-c]pyridin-7(6h)-ones as inhibitors of bet proteins
JP6599979B2 (ja) 2014-09-15 2019-10-30 インサイト・コーポレイション Ｂｅｔタンパク質阻害剤として用いるための三環式複素環化合物
TW201722966A (zh) 2015-10-29 2017-07-01 英塞特公司 Bet蛋白質抑制劑之非晶固體形式
EP4234554A3 (en) 2016-06-20 2023-12-27 Incyte Corporation Crystalline solid forms of a bet inhibitor
JP7290356B2 (ja) * 2019-01-23 2023-06-13 アビスコ セラピューティクス カンパニー リミテッド １，２，３，４－テトラヒドロキノキサリン誘導体、その製造方法および使用
TW202133858A (zh) 2019-11-28 2021-09-16 日商鹽野義製藥股份有限公司 以組合整合酶阻礙劑及抗ｈｉｖ藥為特徵之ｈｉｖ感染症的預防及治療用醫藥
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
CN112409493B (zh) * 2020-08-12 2022-09-30 浙江工业大学 一种重组融合酶及其在乙醛酸甲酯合成中的应用
CN114075212B (zh) * 2020-08-14 2023-05-12 江苏恒瑞医药股份有限公司 稠合三环类衍生物、其制备方法及其在医药上的应用

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000505451A (ja) 1996-02-21 2000-05-09 ダーウィン・ディスカバリー・リミテッド キノロン類およびこれらの治療的使用
AU710825B2 (en) * 1996-02-21 1999-09-30 Darwin Discovery Limited Quinolones and their therapeutic use
US5792774A (en) 1996-02-21 1998-08-11 Chiroscience Limited Quinolones and their therapeutic use
DE19946289A1 (de) * 1999-09-28 2001-03-29 Basf Ag Benzodiazepin-Derivate, deren Herstellung und Anwendung
WO2002012239A1 (fr) * 2000-08-08 2002-02-14 Sanofi-Synthelabo Derives de benzimidazole, leur preparation et leur application en therapeutique
US7026311B2 (en) 2002-01-10 2006-04-11 Abbott Gmbh & Co., Kg Dibenzodiazepine derivatives, their preparation and use
JP2004256531A (ja) * 2003-02-07 2004-09-16 Takeda Chem Ind Ltd 三環性化合物、その製造法および用途
EP1593681A4 (en) 2003-02-07 2007-09-05 Takeda Pharmaceutical TRICYCLIC COMPOUND, PROCESS FOR PRODUCTION AND USE THEREOF
AR056918A1 (es) 2005-01-10 2007-11-07 Tibotec Pharm Ltd 2-oxo-3-ciano-1,6a-diaza-tetrahidro-fluorantenos 1,5,6-sustituidos, proceso de preparacion del compuesto y composicion farmaceutica
MX2008001152A (es) 2005-08-05 2008-04-02 Astrazeneca Ab Benzimidazoles triciclicos y su uso como moduladores del receptor de glutamato metabotropico.
US7939545B2 (en) 2006-05-16 2011-05-10 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
RU2503679C2 (ru) 2007-11-15 2014-01-10 Джилид Сайенсиз, Инк. Ингибиторы репликации вируса иммунодефицита человека
SI2220076T1 (sl) 2007-11-15 2012-05-31 Gilead Sciences Inc Inhibitorji replikacije virusa humane imunske pomankljivosti
WO2009062308A1 (en) 2007-11-16 2009-05-22 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
EA201200631A1 (ru) 2007-11-16 2012-11-30 Джилид Сайенсиз, Инк. Ингибиторы репликации вируса иммунодефицита человека
US8338441B2 (en) * 2009-05-15 2012-12-25 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
GB0908394D0 (en) 2009-05-15 2009-06-24 Univ Leuven Kath Novel viral replication inhibitors
GB0913636D0 (en) 2009-08-05 2009-09-16 Univ Leuven Kath Novel viral replication inhibitors
SG181423A1 (en) 2009-12-23 2012-07-30 Univ Leuven Kath Novel antiviral compounds
PE20130525A1 (es) 2010-07-02 2013-05-05 Gilead Sciences Inc Derivados de acido 2 quinolinil acetico como compuestos antivirales frente a vih
MA34397B1 (fr) * 2010-07-02 2013-07-03 Gilead Sciences Inc Dérivés d'acide napht-2-ylacétique dans le traitement du sida
US8633200B2 (en) 2010-09-08 2014-01-21 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
CA2817896A1 (en) 2010-11-15 2012-05-24 Viiv Healthcare Uk Limited Inhibitors of hiv replication
EP2640705A2 (en) 2010-11-15 2013-09-25 Katholieke Universiteit Leuven Novel antiviral compounds
WO2012102985A1 (en) 2011-01-24 2012-08-02 Glaxosmithkline Llc Isoquinoline compounds and methods for treating hiv
EP2508511A1 (en) 2011-04-07 2012-10-10 Laboratoire Biodim Inhibitors of viral replication, their process of preparation and their therapeutical uses
EP2511273B8 (en) * 2011-04-15 2019-06-26 Hivih Inhibitors of viral replication, their process of preparation and their therapeutical uses
CA2833377C (en) 2011-04-21 2019-02-12 Gilead Sciences, Inc. Benzothiazole compounds and their pharmaceutical use
WO2013002357A1 (ja) 2011-06-30 2013-01-03 塩野義製薬株式会社 Ｈｉｖ複製阻害剤
ES2624984T3 (es) 2011-07-15 2017-07-18 Viiv Healthcare Uk Limited Derivados de ácido 2-(pirrolo[2,3-b]piridin-5-il)-2-(t-butoxi)-acético como inhibidores de la replicación del VIH para el tratamiento del SIDA
US8791108B2 (en) 2011-08-18 2014-07-29 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
WO2013043553A1 (en) 2011-09-22 2013-03-28 Glaxosmithkline Llc Pyrrolopyridinone compounds and methods for treating hiv
US9199959B2 (en) 2011-10-25 2015-12-01 Shionogi & Co., Ltd. HIV replication inhibitor
PT2781519T (pt) 2011-11-15 2019-12-17 St Pharm Co Ltd Novo derivado de pirrolopiridina antiviral e um método de produção do mesmo
US9284323B2 (en) 2012-01-04 2016-03-15 Gilead Sciences, Inc. Naphthalene acetic acid derivatives against HIV infection
US9376392B2 (en) 2012-01-04 2016-06-28 Gilead Sciences, Inc. 2-(tert-butoxy)-2-(7-methylquinolin-6-yl) acetic acid derivatives for treating AIDS
US8629276B2 (en) 2012-02-15 2014-01-14 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
US9034882B2 (en) 2012-03-05 2015-05-19 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
US9006235B2 (en) 2012-03-06 2015-04-14 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
WO2013157622A1 (ja) 2012-04-19 2013-10-24 塩野義製薬株式会社 Ｈｉｖ複製阻害剤
PE20141558A1 (es) 2012-04-20 2014-11-06 Gilead Sciences Inc Derivados de acido benzotiazol-6-il acetico y su uso para tratar una infeccion por vih
CA2876370A1 (en) * 2012-07-12 2014-01-16 Viiv Healthcare Uk Limited Compounds and methods for treating hiv
US8906929B2 (en) 2012-08-16 2014-12-09 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
EP2716639A1 (en) 2012-10-05 2014-04-09 Laboratoire Biodim Inhibitors of viral replication, their process of preparation and their therapeutical uses
EP2716632A1 (en) 2012-10-05 2014-04-09 Laboratoire Biodim Inhibitors of viral replication, their process of preparation and their therapeutical uses
EP2719685A1 (en) 2012-10-11 2014-04-16 Laboratoire Biodim Inhibitors of viral replication, their process of preparation and their therapeutical uses
TW201441197A (zh) * 2013-01-31 2014-11-01 Shionogi & Co Ｈｉｖ複製抑制劑
CN105008358B (zh) 2013-03-13 2017-12-29 百时美施贵宝公司 人免疫缺陷病毒复制的抑制剂
US9580431B2 (en) 2013-03-13 2017-02-28 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
CN105189503B (zh) 2013-03-14 2017-03-22 百时美施贵宝公司 人免疫缺陷病毒复制的抑制剂
WO2015126765A1 (en) 2014-02-19 2015-08-27 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
WO2015147247A1 (ja) 2014-03-28 2015-10-01 塩野義製薬株式会社 Ｈｉｖ複製阻害作用を有する３環性誘導体
EP3144311A4 (en) 2014-05-16 2018-01-03 Shionogi & Co., Ltd. Tricyclic heterocyclic derivative having hiv replication-inhibiting effect
WO2015179448A1 (en) 2014-05-21 2015-11-26 Gilead Sciences, Inc. Therapeutic compounds
JP2017521428A (ja) 2014-07-08 2017-08-03 ヴィーブ ヘルスケア ユーケー リミテッド ウイルス感染症の治療に使用するためのイソインドリン誘導体
UY36221A (es) 2014-07-22 2016-02-29 Viiv Healthcare Uk Ltd Derivados de isoindolinona
AU2015306779B2 (en) 2014-08-27 2017-11-02 VIIV Healthcare UK (NO.5) Ltd Imidazo[1,2-a]pyridine derivatives for use as inhibitors of human immunodeficiency virus replication
TW201720798A (zh) 2015-09-17 2017-06-16 Ｖｉｉｖ醫療保健英國有限公司 苯并氮呯衍生物
EP3383862A1 (en) 2015-12-04 2018-10-10 ViiV Healthcare UK Limited Isoindoline derivatives
JP2018536001A (ja) 2015-12-04 2018-12-06 ヴィーブ ヘルスケア ユーケー リミテッド イソインドリン誘導体
WO2017093930A1 (en) 2015-12-04 2017-06-08 Viiv Healthcare Uk Limited Isoindoline derivatives
JP2019501143A (ja) 2015-12-04 2019-01-17 ヴィーブ ヘルスケア ユーケー リミテッド テトラヒドロイソキノリン誘導体

Also Published As

Publication number Publication date
AU2016271762B2 (en) 2020-01-23
JPWO2016194806A1 (ja) 2018-03-22
MA43120A (fr) 2018-09-05
RU2720145C2 (ru) 2020-04-24
CA2987384A1 (en) 2016-12-08
CN107922423A (zh) 2018-04-17
IL255580A (en) 2018-01-31
US20180162876A1 (en) 2018-06-14
US20200055873A1 (en) 2020-02-20
HK1253539A1 (zh) 2019-06-21
WO2016194806A1 (ja) 2016-12-08
KR20180011267A (ko) 2018-01-31
TW201706275A (zh) 2017-02-16
IL255580B (en) 2020-11-30
CN111138458A (zh) 2020-05-12
AU2016271762A1 (en) 2017-11-30
EP3305789A1 (en) 2018-04-11
CN107922423B (zh) 2020-10-27
JP6614585B2 (ja) 2019-12-04
TWI700284B (zh) 2020-08-01
JP6797464B2 (ja) 2020-12-09
RU2017145082A (ru) 2019-07-01
MX2017015256A (es) 2018-02-19
EP3305789A4 (en) 2018-11-21
RU2017145082A3 (pt) 2019-10-24
US10494380B2 (en) 2019-12-03
SG11201709634QA (en) 2017-12-28
US10870661B2 (en) 2020-12-22
JP2020097568A (ja) 2020-06-25

Similar Documents

Publication Publication Date Title
BR112017025367A2 (pt) derivados tricíclicos contendo nitrogênio tendo atividade inibidora de replicação de hiv
BR112018011103A2 (pt) medicamento para tratar a gripe caracterizada por combinação de inibidor de endonuclease dependente de cap e de fármaco antigripe
CO2017010384A2 (es) Derivados de piridona policíclica sustituida y profármaco de los mismos
UY37847A (es) Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3
SV2016005328A (es) Nuevos derivados de pirazolo pirimidina y su uso como inhibidores de malt1
UY37710A (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana
CL2018001908A1 (es) Nuevos derivados de amonio, un proceso para su preparación y composiciones farmacéuticas que los contienen.
AR063602A1 (es) Derivados de espiroindolinona, formulaciones farmaceuticas que los contienen y su uso en la obtencion de un medicamento para el tratamiento de trastornos oncologicos.
DOP2018000270A (es) Nuevos derivados piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen
BR112019007039A2 (pt) pirrolidinas substituídas e seus métodos de uso no tratamento de fibrose cística
BR112019021853A2 (pt) Compostos de inibidor de vmat2 e composições dos mesmos
PA8657501A1 (es) Derivados de piperida y su uso como agentes antiinflamatorios
BR0306208A (pt) Compostos de dibenzilamina e seu uso farmacêutico
BR112017022654A2 (pt) derivado heterocíclico de 6 membros e composição farmacêutica compreendendo o mesmo
AR049398A1 (es) Derivados de sulfamato y sulfamida; una composicion farmaceutica que los contiene y su uso en la preparacion de un medicamento util para el tratamiento de la epilepsia y trastornos relacionados.
CL2020000086A1 (es) Derivado de anillo fusionado que tiene una actividad inhibidora de monoacilglicerol aciltransferasa 2 (mgat-2).
CO2021005070A2 (es) Inhibición de la proteasa 30 específica de la ubiquitina (usp30)
CO2018010689A2 (es) Derivados de aminotiazol útiles como agentes antivíricos
BR112018016196A2 (pt) derivados do dióxido de iminotiadiazinano como inibidores da plasmepsina v
BR112017026191A2 (pt) compostos tricíclicos e seu uso como inibidores de fosfodiesterase
CO2017008156A2 (es) Derivados de 1-(4-(4-(pirimidin-5-il)tiazol-5-il)piperazin-1-il)etan-1-ona y análogos de piridina de los mismos como moduladores del receptor cxcr3, composiciones que los comprenden y métodos de elaboración
BR112017020081A2 (pt) análogos deuterados de etifoxina, seus derivados e usos dos mesmos
MX2017012396A (es) Derivado de anillo fusionado de 9 elementos.
CO2022001814A2 (es) Compuestos macrocíclicos como agonistas de sting y métodos y usos de los mismos
AR109168A1 (es) Sales de derivados de 2,6-dimetilpirimidona y sus usos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time